Aytu BioPharma(US:AYTU) ZACKS·2026-02-04 00:15分组1 - Aytu BioPharma Inc. reported a quarterly loss of $1.05 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.26, marking an earnings surprise of -303.85% [1] - The company posted revenues of $15.17 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 26.27%, although this represents a decline from year-ago revenues of $16.22 million [2] - Aytu BioPharma shares have increased by approximately 4.2% since the beginning of the year, outperforming the S&P 500's gain of 1.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.10 on revenues of $12.7 million, and for the current fiscal year, it is -$0.54 on revenues of $52.63 million [7] - The Medical - Biomedical and Genetics industry, to which Aytu BioPharma belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Illumina, is expected to report quarterly earnings of $1.26 per share, reflecting a year-over-year increase of 46.5%, with revenues projected at $1.16 billion, up 4.6% from the previous year [9][10]